Please login to the form below

Not currently logged in
Email:
Password:

Waldenstrom's macroglobulinaemia

This page shows the latest Waldenstrom's macroglobulinaemia news and features for those working in and with pharma, biotech and healthcare.

Janssen's Imbruvica fails to win NICE backing in lymphoma

Janssen's Imbruvica fails to win NICE backing in lymphoma

Janssen's Imbruvica fails to win NICE backing in lymphoma. But the agency recommends it on the CDF for another type of cancer. ... There was some positive news for Janssen, however, as Imbruvica received a positive recommendation to treat Waldenström's

Latest news

  • NICE rejects Imbruvica for non-Hodgkin’s lymphoma NICE rejects Imbruvica for non-Hodgkin’s lymphoma

    NICE rejects Imbruvica for non-Hodgkin’ s lymphoma. Draft guidance cites insufficient cost-effectiveness evidence for J&J’ s drug. ... drug. Imbruvica is used to treat Waldenstrom's macroglobulinaemia - a rare type of slow-growing non-Hodgkin's

  • FDA clears Imbruvica as chemo alternative for first-line CLL FDA clears Imbruvica as chemo alternative for first-line CLL

    mantle cell lymphoma (MCL) and the treatment of Waldenström's macroglobulinaemia. ... AbbVie and J&J's drug also achieved partial or complete responses in 82% of patients, compared to 35% of the chemotherapy group.

  • AZ takes majority stake in cancer drug developer Acerta AZ takes majority stake in cancer drug developer Acerta

    Acalabrutinib is a Bruton's tyrosine kinase (Btk) inhibitor in the same class as Janssen/Pharmacyclics/Abbvie's Imbruvica (ibrutinib) drug for chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinaemia, which ... This week it agreed a

  • AZ confirms interest in Acerta takeover AZ confirms interest in Acerta takeover

    as a treatment for chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinaemia. ... Analysts have speculated that AZ's interest in Acerta could draw other possible suitors out of the shadows.

  • Imbruvica filed as first-line leukaemia therapy Imbruvica filed as first-line leukaemia therapy

    of Waldenström's macroglobulinaemia. ... Imbruvica is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor - licensed by Janssen from Pharmacyclics in 2011 in a deal valued at up to $975m.

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics